Seattle Genetics Highlights Data from Denintuzumab Mafodotin (SGN-CD19A) Antibody-Drug Conjugate Program at ASH 2015

ORLANDO, Fla.--(BUSINESS WIRE)--Seattle Genetics, Inc. Buy Lanoxin (Digoxin) without Rx (Nasdaq: SGEN) today highlighted clinical data with denintuzumab mafodotin (SGN-CD19A; 19A) in B-cell malignancies, including diffuse large B-cell lymphoma (DLBCL) and B-lineage acute lymphocytic leukemia (B-ALL), presented at the 57th American Society of Hematology (ASH) Annual Meeting and Exposition taking place in Orlando, Florida, December 5-8, 2015. About Minipress (Prazosin) with no prescription Preclinical data from a novel antibody-drug conjugate (ADC) program called SGN-CD19B in B-cell malignancies will also be featured in an oral presentation. Buy Evecare () with free Rx About 85 percent of non-Hodgkin lymphomas (NHL) are B-cell lineage, and CD19 is broadly expressed across all subtypes of B-cell malignancies. Buy Ipratop with no Rx These two ADCs, 19A and SGN-CD19B, both target CD19 and utilize two of Seattle Genetics’ proprietary payloads, monomethyl auristatin F (MMAF) and a pyrrolobenzodiazepine (PBD) dimer, respectively. Buy Calan (Verapamil) with no Rx The company has initiated the first of two planned phase 2 trials of 19A in DLBCL and plans to advance SGN-CD19B into a phase 1 trial in 2016. “Data presented at ASH from our 19A phase 1 trial in non-Hodgkin lymphoma show encouraging objective response rates, particularly in relapsed DLBCL patients, and a tolerability profile that we believe supports further investigation as part of novel regimens. Buy Hyssop Herb online Based on these data, we recently initiated a phase 2 trial in relapsed DLBCL, and plan to initiate a phase 2 trial in frontline DLBCL during 2016,” said Jonathan Drachman, M.D., Chief Medical Officer and Executive Vice President, Research and Development at Seattle Genetics. http://futurepharmaceuticals.wordpress.com “CD19 is an attractive target for NHL, and there is a clear need for potent, safe and convenient therapies that can be used to improve outcomes for patients.” With more than 15 years of experience and innovation, Seattle Genetics is the leader in developing ADCs, a technology designed to harness the targeting ability of antibodies to deliver cell-killing agents directly to cancer cells. More than 25 ADCs in clinical development utilize Seattle Genetics’ proprietary ADC technology. A Phase 1 Study of Denintuzumab Mafodotin (SGN-CD19A) in Relapsed/Refractory B-Lineage Non-Hodgkin Lymphoma (Abstract #182, oral presentation on Sunday, December 6, 2015 at 7:45 a.m.) Data were reported from 62 patients with relapsed or refractory NHL, including 54 patients with DLBCL, five patients with mantle cell lymphoma and three patients with grade 3 follicular lymphoma. Of the 62 patients, 37 patients (60 percent) were refractory to their last therapy and 25 patients (40 percent) were relapsed. Sixteen patients (26 percent) had received a prior autologous stem cell transplant. The median age of patients was 65 years. The primary endpoints of the ongoing clinical trial are to estimate the maximum tolerated dose and evaluate the safety and tolerability of 19A. In addition, the trial is evaluating antitumor activity, pharmacokinetics, progression-free survival and overall survival. In this study, patients receive 19A either every three weeks or every six weeks. Patients with stable disease or better are eligible to continue treatment with 19A. Key findings from an oral presentation by Craig Moskowitz, M.D. Clinical Director, Division of Hematologic Oncology, Memorial Sloan Kettering Cancer Center, include: The maximum tolerated dose was not exceeded after escalating to 6 milligrams per kilogram (mg/kg) every three weeks. Of the 60 patients evaluable for response, 23 patients (38 percent) achieved an objective response, including 14 patients (23 percent) with a complete remission and nine patients (15 percent) with a partial remission. Thirteen patients (22 percent) achieved stable disease and 24 patients (40 percent) had disease progression. Antitumor activity appeared to be higher in relapsed patients. Of the 25 relapsed patients, 15 patients (60 percent) achieved an objective response, including 10 patients (40 percent) with a complete remission. In the 23 relapsed patients who responded, median duration of response was 47.1 weeks. Among all relapsed patients, median progression-free survival was 25.1 weeks and median overall survival was 56.7 weeks. The most common adverse events of any grade occurring in more than 15 percent of patients were blurred vision (63 percent); dry eye (53 percent); fatigue, keratopathy and photophobia (39 percent each). Ocular symptoms were reported in more than 70 percent of patients. Symptoms were mostly Grade 1/2 and were managed with steroid eye drop treatment and dose modifications. Eighty-eight percent of patients with Grade 3 or 4 keratopathy experienced improvement and/or resolution within a median of five weeks. A Phase 1 Study of Denintuzumab Mafodotin (SGN-CD19A) in Adults with Relapsed or Refractory B-Lineage Acute Leukemia (B-ALL) and Highly Aggressive Lymphoma (Abstract #1328, poster presentation on Saturday, December 5, 2015) Data were reported from 72 adult patients with relapsed or refractory B-ALL and highly aggressive lymphomas, including B-cell lymphoblastic lymphoma (B-LBL) and Burkitt lymphoma. The median age of adult patients was 45 years and the median number of prior systemic therapies was two, with 20 patients (28 percent) having received a prior allogeneic stem cell transplant. The primary endpoints of the ongoing clinical trial are to estimate the maximum tolerated dose and to evaluate the safety of 19A. In addition, the trial is evaluating antitumor activity, pharmacokinetics, progression-free survival and overall survival. In this dose-escalation study, patients received 19A in Schedule A (40 patients) at 0.3 to 3 mg/kg weekly or Schedule B (32 patients) at 4 to 6 mg/kg every three weeks. Key findings include: Of the 56 B-ALL adult patients evaluable for response, six patients (19 percent) treated weekly achieved a composite complete remission (complete remission or complete remission with incomplete platelet or blood recovery) and nine patients (38 percent) treated every three weeks achieved a composite complete remission. The median duration of response was 27 weeks. Fifty-four percent of patients across both schedules achieved cytoreduction of greater than 50 percent. In the ten patients with Philadelphia chromosome positive (Ph+) B-ALL, five patients (50 percent) achieved a complete remission and one patient (10 percent) had a partial remission. Ph+ B-ALL represents 20 to 30 percent of adult patients and carries a dismal prognosis, with higher rates of relapse and lower overall survival. The maximum tolerated dose was not reached in patients treated weekly and was identified at 5 mg/kg in patients treated every three weeks. The most common adverse events of any grade occurring in 25 percent or more of patients treated weekly (40 patients) or every three weeks (32 patients), respectively, were nausea (63 and 41 percent), fatigue (58 and 47 percent), fever (55 and 50 percent), headache (45 and 38 percent) and anemia (43 and 22 percent). In the study, 43 patients (60 percent) developed ocular symptoms, of which 91 percent were Grade 1/2. These included blurred vision (39 percent), dry eye (25 percent) and photophobia (19 percent). Ocular symptoms were managed with steroid eye drop treatment and dose modifications. Keratopathy was observed in 34 patients, of whom 22 patients had Grade 3/4 events. The majority of patients with Grade 3/4 events had improvement or resolution with a median time of approximately four weeks. The 19A phase 1 clinical trials are ongoing. Separately, a randomized phase 2 trial has recently initiated evaluating 19A in combination with R-ICE chemotherapy for second-line DLBCL. In addition, a phase 2 clinical trial in frontline DLBCL is planned to begin in 2016. More information about the 19A clinical trials, including enrolling centers, is available by visiting .clinicaltrials.gov. SGN-CD19B, a Pyrrolobenzodiazepine (PBD)-Based Anti-CD19 Drug Conjugate, Demonstrates Potent Preclinical Activity Against B-Cell Malignancies (Abstract #594, oral presentation on Monday, December 7, 2015 at 11:45 a.m.) A preclinical analysis evaluated the activity of SGN-CD19B, a new ADC consisting of an anti-CD19 antibody attached to a highly potent DNA binding agent called a PBD dimer, in multiple B-cell malignancy models. Data to be presented in an oral session demonstrate that SGN-CD19B exhibits antitumor activity against a broad panel of CD19-expressing B-cell malignancies, inducing durable tumor regressions and improved survival in multiple preclinical models of NHL and B-ALL. Based on these data, a phase 1 clinical trial evaluating SGN-CD19B in NHL is planned to start in 2016. About Denintuzumab Mafodotin (SGN-CD19A) Denintuzumab mafodotin (SGN-CD19A; 19A) is an ADC targeting CD19, a protein expressed broadly on B-cell malignancies. 19A is comprised of an anti-CD19 monoclonal antibody linked to a synthetic cell-killing agent, monomethyl auristatin F (MMAF). The ADC is designed to be stable in the bloodstream, and to release its cytotoxic agent upon internalization into CD19-expressing tumor cells. This approach is intended to spare non-targeted cells and thus reduce many of the toxic effects of traditional chemotherapy while enhancing the antitumor activity. About Non-Hodgkin Lymphoma Lymphoma is a general term for a group of cancers that originate in the lymphatic system. There are two major categories of lymphoma: Hodgkin lymphoma and NHL. NHL is further categorized into indolent (low-grade) or aggressive, including DLBCL. DLBCL is the most common type of NHL. According to the American Cancer Society, more than 71,000 cases of NHL were to be diagnosed in the United States during 2015 and more than 19,000 people would die from the disease. About Acute Lymphoblastic Leukemia Acute lymphoblastic leukemia, also called acute lymphocytic leukemia or ALL, is an aggressive type of cancer of the bone marrow and blood that progresses rapidly without treatment. In ALL, lymphoblasts, which are malignant, immature white blood cells, multiply and crowd out normal cells in the bone marrow. ALL is the most common type of cancer in children. According to the American Cancer Society, more than 6,000 people will be diagnosed with ALL during 2015 and more than 1,400 would die from the disease. About Seattle Genetics Seattle Genetics is a biotechnology company focused on the development and commercialization of innovative antibody-based therapies for the treatment of cancer. Seattle Genetics is leading the field in developing antibody-drug conjugates (ADCs), a technology designed to harness the targeting ability of antibodies to deliver cell-killing agents directly to cancer cells. The company’s lead product, ADCETRIS® (brentuximab vedotin) is a CD30-targeted ADC that, in collaboration with Takeda Pharmaceutical Company Limited, is commercially available in more than 55 countries, including the U.S., Canada, Japan and members of the European Union. Additionally, ADCETRIS is being evaluated broadly in more than 70 ongoing clinical trials in CD30-expressing malignancies. Seattle Genetics is also advancing a robust pipeline of clinical-stage programs, including vadastuximab talirine (SGN-CD33A; 33A), denintuzumab mafodotin (SGN-CD19A; 19A), SGN-LIV1A, SGN-CD70A, ASG-22ME, ASG-15ME and SEA-CD40. Seattle Genetics has collaborations for its ADC technology with a number of leading biotechnology and pharmaceutical companies, including AbbVie, Agensys (an affiliate of Astellas), Bayer, Genentech, GlaxoSmithKline and Pfizer. More information can be found at .seattlegenetics.com. Certain of the statements made in this press release are forward looking, such as those, among others, relating to our planned clinical trials and the therapeutic potential of denintuzumab mafodotin (SGN-CD19A; 19A) and SGN-CD19B. Actual results or developments may differ materially from those projected or implied in these forward-looking statements. Factors that may cause such a difference include the inability to show sufficient activity in the clinical trials and risk of adverse events as denintuzumab mafodotin and SGN-CD19B advance in clinical trials even after promising results in earlier trials. In addition, as our other drug candidates or those of our collaborators advance in clinical trials, adverse events and or regulatory actions may occur which affect the future development of those drug candidates and possibly other compounds using similar technology. More information about the risks and uncertainties faced by Seattle Genetics is contained under the caption “Risk Factors” included in the company’s Quarterly Report on Form 10-Q for the quarter ended September 30, 2015 filed with the Securities and Exchange Commission. Seattle Genetics disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

STOCKHOLM--(BUSINESS WIRE)-- · LobSor plans to submit its regulatory application for EU approval in early 2016 · LobSor in process of planning discussions with the U.S. About Glucotrol (Glipizide) without Rx Food and Drug Administration (FDA) to outline US path to commercialization LobSor Pharmaceuticals, a specialty pharmaceutical company based in Sweden, announced that LECIGon® has achieved its primary endpoint in a late-stage study examining the pharmacokinetics of LECIGon® compared to Abbvie’s Duodopa® in the treatment of advanced Parkinson’s disease. Parlodel (Bromocriptine) without prescription When comparing the levodopa bioavailability during daytime enteral infusion, LECIGon demonstrated superiority over Duodopa with a 38% increase in bioavailability (p value Under its risk-sharing agreement with LobSor for the development of LECIGon, TFS International is responsible for the regulatory strategy, clinical development planning and execution including the regulatory Marketing Authorization (MA) filing. Amaryl (Glimepiride) without Rx No equity transaction is involved in the risk-sharing partnership the commercial upside for both parties relies upon a successful regulatory approval of the MA which is expected in the second half of 2016. About Imaivudine without prescription Discussions with the U.S. Cialis Soft (Tadalafil) Food and Drug Administration (FDA) to outline U.S. Buy Hair Care online commercialization are also planned. The clinical trial was a single centre, two-period, cross-over, open label, randomized study in 11 patients. http://medicalquestionanswers.wordpress.com All patients received both treatments, Duodopa and LECIGon over two consecutive days. Each treatment consisted of a morning dose, a continuous infusion, extra doses as needed, and flushing of the tube at the end of infusion. Patients were randomized to treatment sequence. The clinical trial was successfully managed by the Clinical Development Organization of TFS. “This is a logical development of the concept of levodopa infusion, which is highly effective in treating motor and non-motor fluctuations in advanced Parkinson’s disease”, said Associate Professor Dag Nyholm, principal investigator at the neurology department, Uppsala University Hospital, Sweden. “The results are in line with our expectations.” "The results of the study highlight the benefits of LECIGon for advanced PD patients” said Professor Angelo Antonini director of the Parkinson Unit at the Hospital San Camillo in Venice. “Achieving these positive clinical results with significantly lower levodopa dose is very important because it may reduce adverse events and improve treatment accessibility. Furthermore, the smaller pump system will likely be considered as a great leap forward by the patients.” “We are extremely pleased with the positive results seen in this trial,” said Patricia A. Mosher, EVP, Global Clinical Development at TFS. “Our team worked very effectively in the execution of this trial to support aggressive timelines that were defined in June of 2014 when we entered into this agreement”. We are pleased with the results of the EU registration study for LECIGon”, said Roger Bolsoy, President of LobSor Pharmaceutical. “Our strategy has initially focused on Europe and we anticipate filing for approval in early 2016. We are also in the midst of preparing for a pre-IND meeting with the FDA to discuss the pathway to commercialization in the US. If approved, LECIGon will serve as an optimal treatment option for advanced PD patients.” Information about LECIGon LECIGon is a proprietary gel formulation of levodopa, carbidopa, and entacapone for continuous intestinal administration through a proprietary small, lightweight ambulatory pump system. The intention is to offer a treatment system with an improved safety profile, maintained clinical efficacy, enhanced user convenience, and thus improved Quality of Life compared to existing advanced treatment options. Adding entacapone to levodopa/carbidopa results in a superior bioavailability of levodopa and is expected to reduce the daily levodopa dose needed to maintain a clinical effect. A reduction in daily levodopa exposure is expected to reduce adverse levodopa-related side effects, including exposure to higher levels of metabolic byproducts such as homocysteine and 3-OMD. Continuous intestinal delivery, tailored for the individual patient, has been shown to secure a smooth levodopa plasma level, thereby offering a true continuous dopaminergic stimulation and resulting in a predictable and stable clinical effect. Information about LobSor Pharmaceuticals LobSor Pharmaceuticals is privately owned via LobSor Holding AB and based in Uppsala, Sweden. The founders and main owners of the company, Roger Bols"oy and Ulf Ros en have extensive experience in the development, sales, and marketing of pharmaceutical products and medical devices – with a particular focus on advanced Parkinson’s disease. The Company’s first product – LECIGon has been developed in close collaboration with Recipharm, TFS International and internationally renowned clinical experts – together with active support from investors. Information about TFS TFS International is the leading global mid-size clinical Contract Research Organization (CRO). Founded in 1996 in Sweden, TFS currently operates in over 20 countries throughout Europe, USA, Canada and Japan and employs more than 700 professionals. TFS core therapeutic areas of expertise are Oncology, Immunology, Dermatology, Ophthalmology, CNS, Cardiology and Endocrinology. Through two business areas, TFS DevelopTM and TFS PeopleTM, TFS provides services worldwide as end-to-end solutions or tactical functional services. Detailed information about TFS, its business offerings, global locations and recent press releases can be obtained through .tfscro.com This information was brought to you by Cision news.cision.com

. Buy Garcinia Cambogia online About Grisactin (Griseofulvin) without prescription DUBLIN--(BUSINESS WIRE)--Research and Markets (.researchandmarkets.com/research/jg98wh/viral) has announced the addition of the "Viral Conjunctivitis - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Viral Conjunctivitis, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. http://mdreview.wordpress.com Hemocyte with free Rx Buy Diovan Hct (Valsartan-Hydrochlorothiazide) with free Rx It also reviews key players involved in the therapeutic development for Viral Conjunctivitis and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. About DDAVP (Desmopressin) Renagel (Sevelamer Hydrochloride) with no prescription It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Drug Profiles APD-209 astodrimer EKCCide-I FST-100 PP-001 Trisialic Acid Companies Mentioned Adenovir Pharma AB NanoViricides, Inc. Panoptes Pharma Ges.m.b.H. Shire Plc Starpharma Holdings Limited For more information visit .researchandmarkets.com/research/jg98wh/viral

Jubilant DraxImage lanca o HICON® na Col^ombia

MONTREAL--(BUSINESS WIRE)--Jubilant DraxImage Inc. Clomid (Clomiphene) without Rx (“DraxImage”) tem o prazer de anunciar a entrega da primeira remessa comercial do HICON® - soluc~ao de iodeto de s odio (I-131 - USP) - hoje para Bogot a, Col^ombia. “Este e um marco significativo para a empresa, `a medida que comecamos a expandir o alcance geogr afico desta importante terapia de ablac~ao da tireoide para m edicos e pacientes na Am erica do Sul”, indicou o presidente da DraxImage, Martyn Coombs. O HICON®, uma soluc~ao de iodeto de s odio (I-131), e indicado para o tratamento de doencas da tiroide, como o hipertireoidismo e c^ancer da tiroide. Sumycin (Tetracycline) with free Rx Pacientes que sofrem destas condic~oes da tiroide ter~ao acesso agora ao tratamento com iodo radioativo aprovado pela INVIMA. Reminyl (Galantamine) A INVIMA e a ag^encia colombiana reguladora de produtos farmac^euticos. Glipizide with free Rx Utilizando o sistema distribuidor propriet ario de preenchimento inteligente da DraxImageTM, o nosso distribuidor local, COMCI, fornecer a c apsulas terap^euticas de I-131 personalizadas e espec ificas para pacientes que necessitam de tratamento para a doenca da tiroide. About Endep (Amitriptyline) with no prescription Isto e particularmente importante devido ao n umero crescente dos casos de c^ancer de tiroide sendo diagnosticados. Buy Eyebright online Especificamente, existem quase 2.500 novos casos diagnosticados de c^ancer de tireoide todos os anos na Col^ombia, afetando predominantemente mulheres entre 25 e 65 anos de idade. Como o principal fabricante e fornecedor de I-131 na Am erica do Norte e da soluc~ao a granel unica aprovada pela FDA, que permite doses terap^euticas individualizadas, espec ificas para pacientes, a Jubilant DraxImage continua seu compromisso de fornecer iodo radioativo de alta qualidade, confi avel e de grau farmac^eutico ao mercado global. No encerramento, o presidente Martyn Coombs da DRAXIMAGE declarou: "Estamos muito satisfeitos de entrar neste importante mercado sul-americano com o HICON® e o Smart-FillTM e estamos ansiosos para expandir em outras areas da regi~ao no futuro. http://cholesterolreviews.wordpress.com Mais importante ainda, estamos orgulhosos de trazer estas opc~oes essenciais de tratamento para a Col^ombia”. Sobre a Jubilant DraxImage Jubilant DraxImage Inc., Jubilant DraxImage Inc., uma subsidi aria da Jubilant Life Sciences, desenvolve, fabrica e comercializa radiof armacos utilizados para o diagn ostico e tratamento de doencas. A empresa se dedica `a medicina nuclear e atende clientes – e, a partir deles, pacientes a n ivel mundial, com produtos de alta qualidade e servicos confi aveis. A DraxImage e l ider de mercado na Am erica do Norte para produtos I-131 (diagn ostico e tratamento dos dist urbios da tireoide e c^ancer), MAA (imagiologia pulmonar de perfus~ao), DTPA (imagiologia renal) e MDP (imagiologia ossea), al em de comercializar produtos como o sestamibi (imagiologia de perfus~ao mioc ardica) e o gluceptato (imagiologia renal e do c erebro). A empresa possui um forte canal de desenvolvimento de novos produtos, com destaque para um gerador de rub idio-82 (PET em Cardiologia)..draximage.com A vers~ao oficial e autorizada do comunicado e a emitida na l ingua original do mesmo. A traduc~ao  e apenas uma ajuda, devendo a mesma ser conferida com o texto na sua l ingua original, que  e a unica vers~ao com validade legal.

Optic Neuropathy Pipeline Review H2 2015 - 5 Companies & 11 Drug Profiles

. Buy Digestion Supplements online About Alfacip (Alfacalcidol) with free prescription DUBLIN--(BUSINESS WIRE)--Research and Markets (.researchandmarkets.com/research/nqk2jn/optic_neuropathy) has announced the addition of the "Optic Neuropathy - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Optic Neuropathy, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. http://cardiobloodreview.wordpress.com Buy Furadantin with no prescription About Benzoyl (Benzoyl Peroxide) with free Rx It also reviews key players involved in the therapeutic development for Optic Neuropathy and special features on late-stage and discontinued projects. The report enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. Garcinia Cambogia () Ventolin (Albuterol (Salbutamol)) with no prescription It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development Inotek Pharmaceuticals Corporation Neurotech Pharmaceuticals, Inc. PharmatrophiX, Inc. Quark Pharmaceuticals, Inc. Regenera Pharma Ltd. Drug Profiles Antibody to Inhibit Sema3A for Glaucoma and Optic Neuropathy BA-240 NT-501 QPI-1007 RPh-201 Small Molecule to Inhibit Sema3A for Glaucoma and Optic Neuropathy Small Molecules for CNS Disorders and Ophthalmology Small Molecules for Ophthalmology, Cardiovascular, CNS and Metabolic Disorders Small Molecules to Agonize TrkB for Ophthalmology and Central Nervous System Synthetic Peptide to Inhibit Connexin for Optic Neuropathy trabodenoson For more information visit .researchandmarkets.com/research/nqk2jn/optic_neuropathy

China Pharmaceutical Market Overview 2015

DUBLIN--(BUSINESS WIRE)--Research and Markets (.researchandmarkets.com/research/j892gq/the) has announced the addition of the "The Pharmaceutical Market: China" report to their offering. We remain bullish on China s pharmaceutical sector despite the slowdown in the economy and political reshuffle. Alesse (Levonorgestrel Bp + Ethinylestradiol Bp) without Rx We do not think the reshuffle will have any adverse changes or cause any reversals to healthcare reform given that the country has been rolling out various healthcare schemes and that a key person overseeing these healthcare reform plans is Vice Premier Li Keqiang, the man who may potentially take over from Premier Wen Jiabao in the reshuffle. Buy Zanaflex (Tizanidine) However, the business environment will potentially be threaten by cost- containment policies as the country will have to contain its ever-growing healthcare expenditure. Risk/Reward Rating China continues to rank fourth out of the 18 key markets in Q1 Asia Pacific Pharmaceutical Risk/Reward Ratings with an unchanged score of 62.5 Its high ranking on the table (just behind developed markets Japan, South Korea and Australia) is largely due to the strong growth potential of the pharmaceutical market that is underpinned by a large and increasingly affluent population and an increasing burden of non-communication diseases. Competitive Landscape The competitive landscape section provides comparative company analyses and rankings by US$ sales and % share of total sales - for the total pharmaceutical sector, as well as the OTC, generics, and distribution sub-sectors. Key Topics Covered: 1. About Viagra Pack-90 () with free prescription SWOT 2. About Flutiair with no prescription Political 3. About Inderal (Propranolol) with free Rx Economy 4. Buy Coral Calcium online Operational Risk 5. http://asthmareview.wordpress.com Industry Forecast 6. Pharmaceutical Market Forecast 7. Healthcare Market Forecast 8. Prescription Drug Market Forecast 9. Patented Drug Market Forecast 10. Generic Drug Market Forecast 11. OTC Medicine Market Forecast 12. Pharmaceutical Trade Forecast 13. Key Risks To The Forecast Scenario 14. Macroeconomic Forecasts 15. Economic Activity 16. Industry Risk Reward Index 17. Asia Pacific Risk/Reward Index 18. China Risk/Reward Index 19. Rewards 20. Risks 21. Market Overview 22. Industry Trends And Developments 23. Epidemiology 24. Healthcare Sector 25. Research And Development 26. Clinical Trials 27. Biotechnology Sector 28. Regulatory Development 29. Regulatory Regime 30. Intellectual Property Issues 31. Pricing Regime 32. Reimbursement Regime 33. Competitive Landscape 34. Pharmaceutical Wholesale 35. Recent Developments Companies Mentioned - AstraZeneca - Bayer - China Shijiazhuang Pharmaceutical Group - Eli Lilly - GlaxoSmithKline - Merck & Co - Merck KGaA - North China Pharmaceutical Corporation - Novartis - Pfizer - Roche - Sanofi - Shanghai Pharmaceutical - Sinopharm For more information visit .researchandmarkets.com/research/j892gq/the

AstraZeneca Purchases US Biologics Manufacturing Facility to Support Growing Pipeline

WILMINGTON, Del.--(BUSINESS WIRE)--AstraZeneca today added to its biologics manufacturing capability in the US with the purchase of a high-tech biologics bulk manufacturing facility from Amgen Inc. About Zovirax (Acyclovir) with free prescription Over time, the LakeCentre facility, located in Boulder, Colorado will increase manufacturing and production capacity to support the company’s extensive portfolio of biologics medicines. AstraZeneca plans to start staffing the facility immediately to support refurbishment and infrastructure improvements. Azelex (Azelaic Acid) without Rx Once complete, the site is expected to be operational and licensed for commercial production by late 2017, providing for additional capacity within the company’s biologics operations. In the longer- term, this site could create up to 400 highly skilled jobs, subject to relevant approvals by the local authorities. Adalat (Nifedipine) without prescription The facility will eventually double the biologics manufacturing capacity in the US to meet the needs of the maturing AstraZeneca pipeline. Femara with free prescription Currently biologics make up 50 percent of the company’s pipeline with more than 120 ongoing programmes, including over 30 in clinical development. Pam Cheng, Executive Vice-President, Operations and Information Technology at AstraZeneca, said: “The addition of the Boulder facility will support the progression of biotech drug candidates across our main therapeutic areas as we continue to bring innovative new treatments to patients. About Man XXX () with no prescription This site will play an important role in our future commercial production and give AstraZeneca and MedImmune, our global biologics research and development arm, the flexibility and capacity to meet the needs of our rapidly growing biologics portfolio.” The new facility in Boulder adds to the expansion of AstraZeneca’s biologics manufacturing capabilities, following the planned biologics manufacturing investment in Sweden, announced in May, and the expansion in Frederick, Maryland, announced in November 2014. The financial details were not disclosed. Buy Cayenne online This investment does not impact AstraZeneca’s financial guidance for 2015. – ENDS – NOTES TO EDITORS About AstraZeneca AstraZeneca is a global, innovation-driven biopharmaceutical business that focuses on the discovery, development and commercialisation of prescription medicines, primarily for the treatment of cardiovascular, metabolic, respiratory, inflammation, autoimmune, oncology, infection and neuroscience diseases. http://medical-reviews.blogspot.com AstraZeneca operates in over 100 countries and its innovative medicines are used by millions of patients worldwide. For more information please visit: .astrazeneca.com

Global Brain Metastasis Therapeutics Pipeline Report 2015 - 23 Companies & 33 Drug Profiles

. Buy Breast Health online Mobic (Meloxicam) DUBLIN--(BUSINESS WIRE)--Research and Markets (.researchandmarkets.com/research/58tc2h/brain_metastasis) has announced the addition of the "Brain Metastasis - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Brain metastasis, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. http://future-pharmaceuticals.blogspot.com Etosid with free prescription Buy Vesicare (Solifenacin) with free prescription It also reviews key players involved in the therapeutic development for Brain metastasis and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. Buy Nolvadex (Tamoxifen) without prescription Buy Cialis Black (Tadalafil + L-Arginine + Giseng + Vitamin B6 + Folic Acid) with free prescription It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development AbbVie Inc. AngioChem Inc. BBB Therapeutics B.V. biOasis Technologies Inc. Bristol-Myers Squibb Company Diffusion Pharmaceuticals LLC e-Therapeutics Plc Exelixis, Inc. GlaxoSmithKline Plc Hutchison MediPharma Limited Komipharm International Co., Ltd. Nektar Therapeutics Nerviano Medical Sciences S.r.l. Novartis AG Oncothyreon Inc. Pfizer Inc. Philogen S.p.A. Phosplatin Therapeutics LLC Puma Biotechnology, Inc. Radius Health, Inc. Sanofi Spectrum Pharmaceuticals, Inc. Tocagen Inc. Drug Profiles dabrafenib mesylate + trametinib dimethyl sulfoxide 2B3-101 ANG-1005 ANG-4043 BT-2111 cabazitaxel cabozantinib s-malate ceritinib dacomitinib etirinotecan pegol ETS-2101 HMPL-813 ipilimumab irbinitinib KML-001 lucanthone hydrochloride MDNA-55 neratinib nimotuzumab NMSE-973 PB-357 PF-06463922 plinabulin PT-112 RAD-1901 radretumab RRX-001 TPI-287 transcrocetinate sodium Vaccine for Metastatic Brain Tumor veliparib vocimagene amiretrorepvec + flucytosine ER X-82 For more information visit .researchandmarkets.com/research/58tc2h/brain_metastasis

Poly (ADP-Ribose) Polymerase 2 (PARP-2) Inhibitors Pipeline Insights Review 2015

. Buy Prandin (Repaglinide) with no Rx DUBLIN--(BUSINESS WIRE)--Research and Markets (.researchandmarkets.com/research/wpnp5n/poly_adpribose) has announced the addition of the "Poly (ADP-Ribose) Polymerase 2 (PARP-2) Inhibitors -Pipeline Insights" report to their offering. Poly (ADP-Ribose) Polymerase 2 (PARP-2) Inhibitors - Pipeline Insights provides the in-depth analysis of the pipeline assets across the Poly (ADP-Ribose) Polymerase 2 (PARP-2) Inhibitors. Buy Beta Carotene online Buy Efavirenz (Efavirenz) The main objective of this report to track competitor pipeline molecules, related research activities, technology, collaborations, in-licensing and out-licensing deals. http://medical-questions-answers.blogspot.com Buy Deltasone (Prednisolone) The Poly (ADP-Ribose) Polymerase 2 (PARP-2) Inhibitors Report helps to identify emerging players with potentially strong product information and create effective counter-strategies to gain competitive advantage. Poly (ADP-Ribose) Polymerase 2 (PARP-2) Inhibitors - Pipeline Insights Report covers the Poly (ADP-Ribose) Polymerase 2 (PARP-2) Inhibitors pipeline molecules at various stages of development like Pre-registration phase, clinical phases (Phase III, Phase II & Phase I), pre-clinical and discovery phases. Ilosone (Erythromycin) with no Rx The Report also provides Poly (ADP-Ribose) Polymerase 2 (PARP-2) Inhibitors related therapeutic assessments by molecule type, route of administration, monotherapy and combination products. About Epanutin without Rx The Report also highlights the discontinued and inactive projects in pipeline for Poly (ADP-Ribose) Polymerase 2 (PARP-2) Inhibitors. Scope - The report provides a Poly (ADP-Ribose) Polymerase 2 (PARP-2) Inhibitors Landscape across the globe - The report provides drug profiles which includes product description, MOA, licensors & collaborators, technology, development partner and chemical information - Coverage of the Poly (ADP-Ribose) Polymerase 2 (PARP-2) Inhibitors pipeline on the basis of target, MOA, route of administration, technology involved and molecule type - The report reviews key players involved in the therapeutics development for Poly (ADP-Ribose) Polymerase 2 (PARP-2) Inhibitors and also provide company profiling - Pipeline products coverage based on various stages of development from NDA filings to discovery. - Provides pipeline assessment by monotherapy and combination therapy products, stage of development and molecule type For more information visit .researchandmarkets.com/research/wpnp5n/poly_adpribose

Global and Chinese Medium Chain Triglycerides Industry Report 2015

. Buy Astragalus online About Duricef (Cefadroxil) without Rx DUBLIN--(BUSINESS WIRE)--Research and Markets (.researchandmarkets.com/research/h238kd/global_and) has announced the addition of the "Global and Chinese Medium Chain Triglycerides Industry, 2010-2020 Market Research Report" report to their offering. Market Research Report on Global and Chinese Medium Chain Triglycerides Industry, 2010-2020 is a professional and in-depth market survey on Global and Chinese Medium Chain Triglycerides industry. The report firstly reviews the basic information of Medium Chain Triglycerides including its classification, application and manufacturing technology. http://doctorconsult.wordpress.com About Emeset with free Rx Buy Seroquel (Quetiapine) without prescription The report then explores global and China s top manufacturers of Medium Chain Triglycerides listing their product specification, capacity, Production value, and market share etc. About Provera (Medroxyprogesterone Acetate) without Rx Dramamine (Dimenhydrinate) with free prescription The report further analyzes quantitatively 2010-2015 global and China s total market of Medium Chain Triglycerides by calculation of main economic parameters of each company. Scope The breakdown data of Medium Chain Triglycerides market are presented by company, by country, and by application. The report also estimates 2015-2020 market development of Medium Chain Triglycerides Industry. The report then analyzes the upstream raw materials, downstream clients, and current market dynamics of Medium Chain Triglycerides Industry. The report makes some proposals for a new project of Medium Chain Triglycerides Industry and a new project of Medium Chain Triglycerides Industry before evaluating its feasibility. The report provides an in-depth insight of 2010-2015 global and China Medium Chain Triglycerides industry covering all important parameters. Key Topics Covered: Introduction of Medium Chain Triglycerides Industry Manufacturing Technology of Medium Chain Triglycerides Analysis of Global Key Manufacturers 2010-2015 Global and China Market of Medium Chain Triglycerides Market Status of Medium Chain Triglycerides Industry Market Forecast of 2015-2020 Global and China Medium Chain Triglycerides Industry Analysis of Medium Chain Triglycerides Industry Chain Global and China Economic Impact on Medium Chain Triglycerides Industry Market Dynamics and Policy of Medium Chain Triglycerides Industry Proposals for New Project Research Conclusions of Global and China Medium Chain Triglycerides Industry For more information visit .researchandmarkets.com/research/h238kd/global_and

Child Abuse - Global Clinical Trials Review, H1, 2015

. Buy Dorzolamide with free Rx DUBLIN--(BUSINESS WIRE)--Research and Markets (.researchandmarkets.com/research/gkqkt9/child_abuse) has announced the addition of the "Child Abuse Global Clinical Trials Review, H1, 2015" report to their offering. "Child Abuse Global Clinical Trials Review, H1, 2015" provides data on the Child Abuse clinical trial scenario. Buy Tadapox (Tadalafil with Dapoxetine) with no Rx Buy Niaspan (Niacin) without prescription This report provides elemental information and data relating to the clinical trials on Child Abuse. Buy Volumizing Shampoo online Buy Kamagra Soft (Sildenafil Citrate) with free Rx It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe. http://webmdhelp.wordpress.com Buy Levlen (Ethinyl estradiol / Levonorgestrel) with free Rx The databook offers a preliminary coverage of disease clinical trials by their phase, trial status, prominence of the sponsors and also provides briefing pertaining to the number of trials for the key drugs for treating Child Abuse. Scope Data on the number of clinical trials conducted in North America, South and Central America, Europe, Middle-East and Africa and Asia-pacific and top five national contributions in each Clinical trial (complete and in progress) data by phase, trial status, subjects recruited and sponsor type Listings of discontinued trials (suspended, withdrawn and terminated) Clinical Trial Overview of Top Institutes / Government Centers for Disease Control and Prevention Duke University National Institute of Mental Health The Johns Hopkins University Yale University Allegheny-Singer Research Institute Boston Medical Center Georgia State University Goethe-Universitat Harborview Injury Prevention & Research Center For more information visit .researchandmarkets.com/research/gkqkt9/child_abuse

Global Hereditary Angioedema (HAE) Pipeline Insights Study 2015

. About Voveran (Diclofenac) DUBLIN--(BUSINESS WIRE)--Research and Markets (.researchandmarkets.com/research/p9sp4m/hereditary) has announced the addition of the "Hereditary Angioedema (HAE)-Pipeline Insights" report to their offering. Hereditary Angioedema (HAE) Pipeline Insights provides an in-depth analysis of the pipeline assets across Hereditary Angioedema (HAE). Buy Spices online About Imodium (Loperamide) with no prescription The main objective of this report is to track competitor pipeline molecules, related research activities, technology, collaborations, and in-licensing and out-licensing deals. http://asthmareview.wordpress.com About Norvasc (Amlodipine) with no Rx The Hereditary Angioedema (HAE) Report helps to identify emerging players with potentially strong product information and create effective counter-strategies to gain competitive advantage. Hereditary Angioedema (HAE) Pipeline Insights Report covers the Hereditary Angioedema (HAE) pipeline molecules at various stages of development, like pre-registration phase, clinical phases (Phase III, Phase II & Phase I), and pre-clinical and discovery phases. Buy Tadacip (Tadalafil) The Report also provides Hereditary Angioedema (HAE) related therapeutic assessments by molecule type, route of administration, monotherapy and combination products. About Desolett The Report also highlights the discontinued and inactive projects in the pipeline for Hereditary Angioedema (HAE). Scope - The report provides a Hereditary Angioedema (HAE) landscape across the globe - The report provides drug profiles which include product description, MOA, licensors & collaborators, technology, development partner and chemical information - Coverage of the Hereditary Angioedema (HAE) pipeline on the basis of target, MOA, route of administration, technology involved and molecule type - The report reviews key players involved in the therapeutics development for Hereditary Angioedema (HAE) and also provides company profiling - Pipeline products coverage based on various stages of development from NDA filings to discovery. - Provides pipeline assessment by monotherapy and combination therapy products, stage of development and molecule type For more information visit .researchandmarkets.com/research/p9sp4m/hereditary.

Cystic Fibrosis Foundation Announces Leadership Transition

BETHESDA, Md.--(BUSINESS WIRE)--The Cystic Fibrosis Foundation today announced that Robert J. About Dexone (Dexamethasone) with free Rx Beall, Ph.D., will step down as president and chief executive officer, effective December 31, 2015. Buy Rheumatrex (Methotrexate) He will be succeeded by Preston W. About Vibramycin (Doxycycline) with free prescription Campbell III, M.D., currently the Foundation’s executive vice president for medical affairs, a position he has held since 1998. During his 35 years with the Cystic Fibrosis Foundation – 21 years as its president and CEO – Beall has had a profound impact on the lives of people with CF. Buy Daivobet without prescription When he joined the Foundation, the median predicted age of survival for a person with the disease was 18 years of age – today it is more than 40 years. Buy Alfacip (Alfacalcidol) without prescription For the first time ever, more than 50 percent of people with CF are over 18 years of age. Buy Raspberry online CF is no longer a pediatric disease. “Since the Foundation was established, people with CF and their families have inspired us to reach milestones that once seemed unachievable,” said Beall. http://pharmaceutical-journal.blogspot.com “When I joined the Foundation in 1980, people with CF and their families had very little reason to hope for a better tomorrow. Now, we have two groundbreaking treatments that attack the underlying cause of the disease, an extensive nationwide network of CF care centers and a community of people with CF who are living longer, healthier lives than ever before.” Beall continued: “Despite these achievements, we know there is still so much work to be done. I am confident that Dr. Campbell, my trusted colleague, will guide the Foundation through our next era of groundbreaking research and care. I would like to thank my colleagues, partners and the families in the CF community for giving me the opportunity to lead this wonderful organization. It has been one of the great pleasures and privileges of my life.” Seamless Transition to New Leadership A CF trailblazer in his own right, Campbell has worked side by side with Beall for nearly two decades. In addition to overseeing the Foundation’s research and drug discovery and development efforts, Campbell directs its clinical trials program, network of care centers and national patient registry database. An accomplished pediatric pulmonologist, Campbell previously served as center director at the Vanderbilt University CF Care Center, where he expanded the program from 30 patients to more than 300 in just five years. Until recently, he continued to provide direct clinical care to patients at the Johns Hopkins CF Care Center. “It is an honor to follow the path laid out by Dr. Beall and to build upon his tremendous achievements,” said Campbell. “This is an exciting time for the Foundation. We are accelerating our mission to pursue daring new research, which we hope will one day lead to a lifetime cure, while we continue to expand services that help people with CF enjoy the best health and quality of life. As always, the needs of people with CF will guide everything that we do moving forward.” Beall and Campbell will work closely together to provide for a seamless transition of leadership and ensure the Foundation’s strong momentum continues. Innovative Approach to Research “Dr. Beall has set a new standard for entrepreneurship in leadership of a nonprofit medical research foundation,” said Francis S. Collins, M.D., Ph.D., director of the National Institutes of Health and co-discoverer of the cystic fibrosis gene. “His willingness to take major risks, while fully aware of the potential for failure, has led to the dramatic advances in the treatment of cystic fibrosis that the entire world now celebrates. While there is still much more to do before cystic fibrosis is vanquished, the momentum is unstoppable. Let us pause to give thanks to Bob – we got this far because he dared to dream.” Beall pioneered the Foundation’s successful venture philanthropy model, which has been a game changer in CF research and drug development. In 1997, he established the Foundation’s Therapeutics Development Program, a unique coalition that has advanced CF drug development through a centralized network of clinical trials and alliances with biotech companies. The program has been responsible for a continuum of breakthrough treatments, including Kalydeco™ and the recently approved Orkambi™, both of which attack the underlying cause of the disease. Unprecedented Accomplishments “We are profoundly grateful for Dr. Beall’s leadership and in awe of his many accomplishments. During his more than three decades with the Foundation, he has had a transformative impact on the CF community,” said Catherine C. McLoud, chair of the CF Foundation Board of Trustees. “It would be difficult to point to another nonprofit leader who has made such a dramatic difference in the lives of people with a disease, and nobody beats Dr. Beall’s record of innovation and passionate commitment to our mission.” About the Cystic Fibrosis Foundation The Cystic Fibrosis Foundation is the world s leader in the search for a cure for cystic fibrosis. The Foundation funds more cystic fibrosis research than any other organization, and nearly every CF drug available today was made possible because of Foundation support. Based in Bethesda, Md., the Foundation also supports and accredits a national care center network that has been recognized by the National Institutes of Health as a model of care for a chronic disease. The Cystic Fibrosis Foundation is a donor-supported nonprofit organization. For more information, go to .cff.org.

Two studies published in PLOS Pathogens this month shed further light on the effect of neutralizing antibodies in the steep challenge facing researchers to develop a vaccine against AIDS/HIV. About Dexone (Dexamethasone) with free Rx Nabs are immune proteins that can recognize, bind to, and trigger the elimination of a virus. Buy Rheumatrex (Methotrexate) Image credit: Dr. About Vibramycin (Doxycycline) with free prescription Alexandra Trkola The search for an effective vaccine for AIDS/HIV has long been a battle for scientists and researchers around the world. Buy Daivobet without prescription Although HIV incidence have remained stable around the world at 50,000 new infections per year, a cure still remains to be found. Neutralizing antibodies are immune proteins that can recognize, bind to, and trigger the elimination of a virus before it can establish a chronic infection. Buy Alfacip (Alfacalcidol) without prescription Nabs have previously been researched as a tool against HIV and AIDs. Buy Raspberry online In a study last year, scientists discovered for the first time how to create Nabs in those already infected with HIV-1. http://pharmaceutical-journal.blogspot.com Dr. Julia Overbaugh, from the Fred Hutchinson Cancer Research Center in Seattle, WA, and her team, focused on the role of Nabs in those "superinfected" with HIV, which is defined as those sequentially infected at least twice with HIV by different sexual partners. Results from 21 women who were tested suggest that Nabs mount a broad and potent response against diverse HIV subtypes. It is hoped that that this particular response can be mediated at least in part by polyclonal antibodies, which can then target different aspects of the virus. These findings follow on from the team s previous research into the superinfected. In that study, it was discovered that those infected twice had a more potent antibody response to the virus - which inhibited the virus from replicating - compared with women who have only been infected once. Dr. Overbaugh hopes further research can be done on those superinfected, stating further research may "provide insight to the development of a diverse Nab response with multiple epitope specificities." Direct cell to cell transmission more prone to mutation strains The second study published in PLOS Pathogens focused on Nabs effect on those infected with HIV/AIDS by cell-to-cell contact. Dr. Alexandra Trkola from the University of Zurich, Switzerland, and her colleagues, developed an assay that can specifically test the potency of Nabs to prevent direct cell-to-cell transmission of HIV. By establishing an assay system, the free virus infection is restricted, resulting in infections only occurring through cell-to-cell transmissions. Researchers were able to test whether a large selection of Nabs could prevent cell-to-cell transmission of different HIV strains. Although Nabs showed an overall decrease in activity, losses varied substantially depending on the antibody and virus strain examined. Scientists also discovered certain Nabs still retained activity during cell-to-cell transmission for individual viruses. However, this was generally not linked to a high potency of the free virus, but instead, displayed Nabs inhibiting prior to the binding of the virus to the CD4 receptor on T cells. Mathematical analysis showed that when the virus was transmitted via cell to cell transmission, it was substantially more prone to give rise to mutation strains that can escape immune control compared to free virus transmissions. Dr. Trkola said: "This highlights the importance of controlling virus replication via the cell-cell transmission pathway even if the contribution of this transmission should provide to occur to a less extent than free virus spread in infected individuals." Written by Peter Lam

Scientists 'hack' common gut bacterium

In a new study published in the journal Cell Systems, researchers reveal how they have engineered a common gut bacterium to have new functions, enabling control of gene expression in the intestinal tracts of mice. The researchers hope they can one day use intestinal signaling to modify gene expression via engineered bacteria, which could offer new treatment strategies for numerous health conditions. Study leaders Timothy K. Cozaar (Losartan) without Rx Lu and Christopher Voigt, of the Massachusetts Institute of Technology (MIT), and colleagues say their study could pave the way for the development of microbes that detect illness in the gut or that can deliver drugs. Researchers have been increasingly investigating how to engineer gut bacteria so it holds therapeutic potential. Sinequan (Doxepin) with no Rx Last year, for example, Medical News Today reported on a study by researchers from Vanderbilt University in Nashville, TN, which detailed how Escherichia coli bacteria were modified to reduce food intake and obesity in mice. The MIT team notes, however, that E. About Styplon () with no Rx coli is not present in the gut in abundance - it can be cleared within days of introduction. About Cyclosporine As such, they turned their attention to Bacteroides - specifically, a species called Bacteroides thetaiotaomicron. "Compared to E. Aricept (Donepezil) without prescription coli, Bacteroides populations exhibit low variation in abundance and long-term colonization," the authors explain. Buy Prenatal Vitamins online "B. http://futurepharmaceuticals.wordpress.com thetaiotaomicron is both prevalent (present in 46% of humans) and abundant [...] making it a promising organism for both understanding and manipulating the gut environment." In addition, the researchers say these bacteria are able to express genes "on demand" and engage in long-term interactions with human cells and other gut bacteria. This means a form of this bacteria engineered to deliver drugs and its expressed genes could remain in the gut for longer. Genes in engineered bacterium expressed based on what mouse is fed To engineer B. thetaiotaomicron, the MIT team combined a number of tools researchers have previously used to engineer other bacteria, including promoters, ribosome-binding sequences, memory switches and CRISPR interference, and introduced them to the bacterium. "We then showed that genetic devices could be implemented in the bacteria and be shown to function in the context of the mouse gut microbiome." says Lu. Explaining what these findings mean, Voigt says: "The culmination of the work is not only do you have an engineered bacterium that s colonized the mouse gut, but you can turn on which genes in the bacterium are active based on what you feed the mouse. That s really something new. It allows you to control what the bacterium is doing at the site of where it s operating." The researchers hope to move their work to human trials, but note there are some barriers to overcome first. For example, in this study, the mice had to be given antibiotics before their gut could be colonized with B. thetaiotaomicron. Also, the team says they need to demonstrate that the bacteria can be engineered to perform more complex functions, such as the ability to respond to a variety of sensory inputs. The researchers say the long-term goal is to use intestinal signaling to modify gene expression via engineered bacteria, which could offer new treatment strategies for a variety of health conditions. "The big picture is that the bacteria that live in us or on us impact human health in very significant ways and the existing techniques we have to modulate the microbiome - taking antibiotics or changing our diet - are relatively limited," notes Lu. "We re hoping that with these tools to precisely engineer the intimate interface between bacteria and humans we re going to be able to tackle some major health-related problems." Written by Honor Whiteman

Half of breast cancers 'could be slowed with a common hormone'

. http://md-opinion.blogspot.com Buy Nerves online About Caverta (Sildenafil Citrate) with free Rx About Combidol without prescription About Proventil (Albuterol) with free prescription Viagra Capsules (Sildenafil Citrate) Buy Aygestin (Norethisterone Bp) with no prescription

Can playing Tetris reduce intrusive memories?

For individuals with post-traumatic stress disorder, unwanted visual memories are a common symptom. Aralen (Chloroquine Phosphate) with no prescription But a new study suggests that playing computer games 24 hours after a traumatic event may reduce the occurrence of such memories. Reactivating the emotional memories of participants prior to them playing a computer game reduced occurrence of related unwanted memories in the following week. It is estimated that around 7-8% of the US population will experience post-traumatic stress disorder (PTSD) at some point in their lives, with women more likely to develop the condition than men. PTSD is triggered by exposure to a traumatic event. Voltaren (Diclofenac Sodium) with free prescription Symptoms include feeling tense, sleep problems, feelings of guilt or depression and frightening thoughts. Buy Glycomet (Metformin) with free prescription One of the most common symptoms is repeated visual memories of the event that triggered the disorder. People with PTSD often remember moments of their terrifying ordeal in vivid detail and feel as if they are reliving the event over and over, which can severely impact day-to-day life. Psychotherapy is one of the primary treatments for PTSD. Buy Clotrimazole This may include cognitive restructuring, which involves helping people make sense of their bad memories in an attempt to help them cope. About Cialis Light Pack-90 () But according to the study researchers, strategies to prevent such memories are limited. "Currently, there are recommended treatments for PTSD once it has become established, that is, at least 1 month after the traumatic event, but we lack preventative treatments that can be given earlier," explains senior study author Emily Holmes, of the Medical Research Council Cognition and Brain Sciences Unit in the UK. Past studies have indicated that people who played the computer game Tetris within 4 hours of watching video footage of traumatic events were less likely to have fewer unwanted memories of those events. However, Holmes and colleagues note that it is unrealistic to expect people who are involved in a traumatic event to play a computer game in the 4 hours following. Buy Multi Oil Blends online But could doing so within 24 hours help reduce occurrence of unwanted memories? Combination of memory reactivation and Tetris reduced intrusive memories To test whether this might be the case, the researchers conducted two experiments that investigated the theory of memory reconsolidation - the idea that long-term memories can be recalled and modified. The idea was to reactivate old emotional memories of participants and see whether the reoccurrence of these memories could be reduced by computer game play. In the first experiment, the researchers induced intrusive memories in 52 participants by showing them a 12-minute film of traumatic events, such as a man drowning at sea or a young girl being hit by a car. Twenty-four hours after watching the film, half of the participants were shown stills from it as a way of reactivating their memories. http://mdreview.wordpress.com They then took part in a 10-minute filler task - allowing time for memory reconsolidation to begin - followed by 12 minutes of playing Tetris. The other half of the participants acted as controls, only taking part in the filler task before sitting quietly for 12 minutes. Over the next week, all participants were required to keep a diary of any intrusive memories that occurred - defined as "scenes of the film that appeared spontaneously and unbidden in their mind." The team s findings - published in the journal Psychological Science - revealed that the participants whose memories were reactivated before playing Tetris experienced fewer intrusive memories from the film than the control group. This finding was confirmed in the second experiment, in which four groups of participants performed the same tasks. In this experiment, however, the team also tested whether memory reactivation alone or Tetris alone could reduce occurrence of intrusive memories. They found it was only the use of memory reactivation and Tetris combined that led to fewer intrusive memories. Commenting on their results, study co-author Ella James, also of the Medical Research Council Cognition and Brain Sciences Unit, says: "Our findings suggest that, although people may wish to forget traumatic memories, they may benefit from bringing them back to mind, at least under certain conditions - those which render them less intrusive." Holmes notes that their research is in its early stages and further studies are required, but she says they hope to develop their approach, with the aim of creating a potential strategy to reduce intrusive memories for people with PTSD and other trauma-related conditions. "Better treatments are much needed in mental health," she adds. "We believe the time is ripe to use basic science about mechanisms - such as research on memory reconsolidation - to inform the development of improved and innovative psychological treatment techniques." In August 2014, Medical News Today reported on a study suggesting the way a person s memory is processed may influence their risk of developing PTSD. Published in the journal Clinical Psychological Science, the study suggests people who recall higher numbers of external details related to the traumatic event - such as editorial statements - may be at higher risk for PTSD. Written by Honor Whiteman

Independence Day fireworks 'cause significant rise in air pollution'

July 4th has been celebrated as the birth of American independence since 1776. Buy Avana (Avanafil) with free Rx Tonight, the sky will be illuminated with stunning fireworks displays that are taking place all over the US. About Amaryl (Glimepiride) But according to a new study, such festivities may have an unintended consequence - a significant increase in air pollution. Fireworks set off over the US on the evening of July 4th cause an average 42% rise in air pollution, according to the researchers. Published in the journal Atmospheric Environment, the study identifies a rise in fine particulate matter, or PM2.5 - particles that are 2.5 micrometers in diameter and smaller - on the evening of July 4th and the morning of July 5th. According to the US Environmental Protection Agency (EPA), these small particles are a health concern; they can easily pass through the throat and nose to the lungs, which can trigger shortness of breath, coughing, wheezing and asthma attacks, as well as long-term health effects - such as stroke and heart attack and death from lung and heart disease. It is well known that fireworks can present health risks. Astelin (Azelastine) with no Rx Last year, a Spotlight feature from Medical News Today noted that firework injuries - such as burns and other injuries to the hands, eyes and legs - increased by 30% compared with the previous year. According to the researchers of this latest study - including Dian J. About Ciloxan with free Rx Seidel of the National Oceanic and Atmospheric Association (NOAA) Air Resources Laboratory in College Park, MD - previous studies had identified increases in air pollutants during and following fireworks displays. "But no study to date has explored fireworks effects on air quality over large regions using systematic observations over multiple years to estimate typical regional PM [particulate matter] increases," they note. Concentrations of fine particulate matter 42% higher on evening of July 4th Seidel and study co-author Abigail N. Dilantin (Phenytoin) with no prescription Birnbaum, of the University of Maryland and student intern at NOAA, set out to address this research gap, assessing the air quality of 315 sites across the US on every 4th July between 1999 and 2013. "We chose the holiday, not to put a damper on celebrations of America s independence, but because it is the best way to do a nationwide study of the effects of fireworks on air quality," says Siedel. The researchers analyzed the hourly concentrations of fine particulate matter on the evening of July 4th, comparing them with those of the days before and after, The team found that on average, concentrations of fine particulate matter were 42% higher on the evening of July 4th, compared with the days before and after the holiday. Buy Liver Detox online Levels reached their highest between 9 pm and 10 pm, with increases beginning at 8 pm. http://anti-infectives-opinion.blogspot.com The increases lasted until around midday on July 5th. The researchers identified variations in PM2.5 concentrations between air quality monitoring sites, which appeared to be dependent on weather conditions and how close the fireworks were to the site. For example, concentrations were around 370% higher on the evening of July 4th at one site where the fireworks were set off in a field adjacent to it - which the team says is at a level well above the maximum 24-hour limit of 35 mcg per cubic meter set by the EPA. Commenting on the findings, Seidel says: "These results will help improve air quality predictions, which currently don t account for fireworks as a source of air pollution. The study is also another wake-up call for those who may be particularly sensitive to the effects of fine particulate matter." The team notes that while the EPA do not regulate fireworks, they do recommend that individuals who are sensitive to air pollution - such as those with asthma - watch fireworks displays from a distance and ensure they have any required medication to hand. Written by Honor Whiteman

'Artificial pancreas' holds promise for easier control of type 1 diabetes

. Buy L-Tryptophan online Isordil (Isosorbide dinitrate) with no Rx esearchers have created an implantable "artificial pancreas" that they say could eliminate the use of insulin injections and pumps for people with type 1 diabetes. People with type 1 diabetes have to endure multiple insulin injections daily or use an insulin pump to control their condition, but researchers say the artificial pancreas could offer a simpler management method. Francis J. http://cardiobloodreview.wordpress.com Buy Champix without prescription About Hard On Oral Jelly (Sildenafil Citrate) with free prescription Doyle and colleagues from the University of California-Santa Barbara reveal how the device can continuously measure an individual s blood glucose levels and automatically deliver insulin when required. They publish the details of their creation in the journal Industrial & Engineering Chemistry Research. According to the American Diabetes Association, around 1.25 million adults and children in the US have type 1 diabetes, of whom around 200,000 are under the age of 20. Type 1 diabetes is an autoimmune disease in which the pancreas stops producing the hormone insulin, which can result in dangerously high or low blood glucose levels. People with type 1 diabetes must measure their blood glucose levels by pricking their fingers for blood regularly throughout the day, using the measurements to calculate the insulin dose needed. To deliver insulin to the body, individuals must either inject themselves with the hormone multiple times throughout the day, or have a continuous infusion of the hormone via an insulin pump. But Doyle and colleagues say their new device could make managing type 1 diabetes much easier, abolishing the need for finger pricking and multiple injections. Optimum glucose levels maintained 78% of the time in computer tests In their study, the researchers detail the creation of a fully implantable artificial pancreas that uses an algorithm to monitor patients blood glucose levels and calculate the insulin dose needed, which is then automatically delivered to the body. On conducting computer testing of the device - involving simulation of a rise and fall in glucose levels that occurs after meals throughout the day - the team found it maintained the optimum blood glucose range of 80-140 mg/dL 78% of the time, "with no time spent in hypoglycemia." Speaking about the device at a press conference when it was first unveiled back in January, Doyle says he believes it has the potential to transform type 1 diabetes management, adding: "The closed-circuit system provides much tighter control at an unprecedented level to minimize complications and to improve the quality of life. It will have immediate benefits, as it will lower health care costs in the country and it will reduce the amount of decisions people with diabetes need to make on a constant basis." The researchers say they hope the artificial pancreas will be available for type 1 diabetes patients in the next 5 years, though the next step for the team is to conduct animal testing to "evaluate the in vivo performance" of the device. This is not the first artificial pancreas to be developed for type 1 diabetes. Buy Effexor Xr (Venlafaxine) with no prescription Buy Atripla (Efavirenz+Emtricitabine+Tenofovir) with no prescription In November 2014, Medical News Today reported how a team of Canadian researchers showed how two versions of an external artificial pancreas were more effective than an insulin pump for managing the condition. Written by Honor Whiteman